Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein farnesyltransferase (FTase) is a key enzyme responsible for the posttranslational modification known as farnesylation. This process involves the covalent attachment of a 15-carbon isoprenoid lipid, called a farnesyl group, to specific proteins that contain a C-terminal CaaX motif (where "C" is cysteine, "a" represents aliphatic amino acids, and "X" can be several different amino acids). The modification occurs at the cysteine residue near the protein's C-terminus and results in increased membrane association and altered protein-protein interactions. Because many oncogenic mutations require proper membrane localization via farnesylation (notably mutant Ras), FTase has become an important target for anti-cancer drug development.
Inhibition of farnesylation of target proteins
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein Farnesyltransferase (FTase).